Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Collegium Pharmaceutical (COLL) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for Collegium Pharmaceutical (COLL) over the last 10 years, with Q3 2025 value amounting to $31.5 million.

  • Collegium Pharmaceutical's Net Income towards Common Stockholders rose 23751.47% to $31.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $58.4 million, marking a year-over-year decrease of 3403.28%. This contributed to the annual value of $42.4 million for FY2024, which is 788.23% down from last year.
  • Per Collegium Pharmaceutical's latest filing, its Net Income towards Common Stockholders stood at $31.5 million for Q3 2025, which was up 23751.47% from $12.0 million recorded in Q2 2025.
  • Collegium Pharmaceutical's Net Income towards Common Stockholders' 5-year high stood at $74.0 million during Q2 2021, with a 5-year trough of -$25.0 million in Q4 2021.
  • Its 5-year average for Net Income towards Common Stockholders is $11.2 million, with a median of $12.0 million in 2025.
  • Per our database at Business Quant, Collegium Pharmaceutical's Net Income towards Common Stockholders crashed by 45978.73% in 2021 and then surged by 441509.85% in 2023.
  • Over the past 5 years, Collegium Pharmaceutical's Net Income towards Common Stockholders (Quarter) stood at -$25.0 million in 2021, then surged by 71.24% to -$7.2 million in 2022, then soared by 543.67% to $31.9 million in 2023, then plummeted by 60.75% to $12.5 million in 2024, then skyrocketed by 151.33% to $31.5 million in 2025.
  • Its last three reported values are $31.5 million in Q3 2025, $12.0 million for Q2 2025, and $2.4 million during Q1 2025.